David Cunningham to Esophageal Neoplasms
This is a "connection" page, showing publications David Cunningham has written about Esophageal Neoplasms.
Connection Strength
0.090
-
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 2024 Jan; 9(1):102202.
Score: 0.090